Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC” ...

Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH) is a disease that occurs when ...

The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The invasive nature of lipid biopsies has lead researchers to dedicate more efforts to unveiling noninvasive diagnostic ...

Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic ...

Excessive alcohol consumption is a significant public health concern, responsible for approximately 6% of all deaths and ...

THR-beta agonists are the only medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe form of liver disease. Learn more.

Sagimet Biosciences Inc. (Nasdaq: SGMT), clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial ...

Leg-spinner Yuzvendra Chahal's maiden six-wicket for India as the hosts beat England by 75 runs in the third and final Twenty20 International ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a polygenic disorder influenced by multiple genes, but their ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...